Good morning.
The retail trading revolution just got a huge boost. Regulators are dismantling the $25,000 day trading rule that's locked out smaller investors since the dot-com crash, while Martin Shkreli reminded everyone why having the right Twitter follows still matters for spotting breakout trades.
Meanwhile, Amazon might finally be ready to break out of its flat-line performance against the rest of the Magnificent Seven after Wells Fargo upgraded it to a buy. And Intel's comeback story is gaining momentum—after Nvidia's $5 billion investment and government backing, now Apple is reportedly in talks to join the party.
Outlook: when regulators make trading easier and Intel starts looking investable, you know something's shifted.
In partnership with Fenchurch Legal
Get fixed yield from high-volume legal claims
Fenchurch lends to law firms, not plaintiffs
Most litigation finance firms make risky, binary bets on large, one-off cases.
But Fenchurch Legal takes a different approach.
Instead of backing one-off lawsuits, Fenchurch lends directly to law firms, to fund the costs of handling thousands of small, consumer cases, which covers pre-trial disbursements like court filing fees and expert reports. The funding is structured as a loan, which is repayable regardless of the case outcome.
With Fenchurch's model, investors get paid a fixed return — win or lose.
Specifically, they fund high-volume, low-value consumer claims. These are procedural cases with strong precedent, and far better risk-adjusted economics.
Oh, and every litigated case they fund is backed by ATE insurance (after-the-event). That means even if a case is lost, the insurer steps in and repays Fenchurch in full.
Fenchurch CEO Louisa Klouda
Fenchurch is currently offering secured note options across 2–3 year terms
Target yields in the 11–13% range.
Interest is distributed quarterly, and international investors are welcome.
Capital protected through layered security (borrower assets, case proceeds, and insurance protection)
This is a stable, income-generating product in a completely uncorrelated asset class. It's one of the few ways to access litigation finance without taking big risk.
Our friends at Alts.co are putting together an SPV to give you special terms.
Please support our partners!
📰 Market Headlines
Stocks slipped for a second straight day after mixed Fed signals, with Chair Powell warning valuations look “fairly high” while other officials pushed for deeper cuts.
The S&P 500 fell 0.3%, the Dow dropped 0.4%, and the Nasdaq slid 0.3%.
US futures losses bled into their third straight day, down 2%
Regulators are tearing down the $25,000 day trading wall. FINRA approved amendments to replace the equity minimum rule that's kept smaller accounts from pattern day trading since 2001. The change needs SEC approval, but if it passes, anyone will be able to execute four or more day trades in five days regardless of account size. The original rule was implemented during the dot-com crash to protect small traders from "excessive risks.”
Martin Shkreli's Twitter game is still unmatched for spotting biotech rockets. Those of his Twitter followers who caught this signal got to watch QURE rise 248% to $47.50 after trading began yesterday.
1 hour before markets opened: Shkreli tweeted that $QURE would 5-10x (Uniqure announced a successful gene therapy drug for Huntington’s disease)
9 minutes before the opening bell: he tweeted that FDA approval was inevitable for $QURE’s treatment and called it a potential $2B revenue drug
The stock rose 248%
Shkreli’s victory lap: "if you want to sell some $QURE go ahead but NEVER EVER SAY SHKRELI AINT DO NOTHIN FOR ME."
Amazon could finally break its slump after Wells Fargo's upgrade to buy. The stock has been dead flat this year, and it’s the worst performer among the Magnificent 7. But analyst Ken Gawrelski sees "increased conviction in AWS revenue acceleration" driven by the $4 billion Anthropic investment and their Project Rainer AI supercomputer. He's forecasting 22% AWS revenue growth in 2026 versus the 18% Wall Street consensus, setting a $280 AMZN price target (currently $220).
Is Intel about to become the comeback story everyone wants in on? Apple is reportedly in early talks about investing in the chipmaker, which would add another marquee name to Intel's growing list of backers. Intel shares jumped 7% on the Apple news as investors wonder if they, too, should throw money at the chip company. So far:
Nvidia already committed $5 billion to Intel for PC and data center chip collabs
SoftBank dropped $2 billion on INTC last month
The US government owns a 10% stake through CHIPS Act funding
Meanwhile, Alibaba surged 8% after pledging to boost AI spending beyond its $50 billion target. The announcement lifted Chinese chipmakers like SMIC (+5.7%) and Baidu (+3%) as investors bet Beijing’s tech giants will keep pace with the global $4 trillion AI race.
😱 Fear and Greed Index
🪙 Crypto
Hyperliquid rival Aster handled $23 billion in perpetual futures trades on September 24, more than double what Hyperliquid did that day. Its token hit $2.40, pushing the valuation to $20 billion.
The SEC's new rules cut crypto ETF approval times to 75 days or less, down from 270.
The platform’s USDF stablecoin supply quadrupled to 262 million in a week.
🤖 AI/Future/Tech News
Microsoft added Anthropic models to its 365 Copilot assistant, reducing reliance on OpenAI.
OpenAI’s massive "Stargate" project expanded its scope and reached nearly 70% of its 10-gigawatt compute goal.
🕵 Top Stocks On r/WallStreetBets Today
Reddit never sleeps, and the mentions prove it. We’re especially intrigued by two things:
Intel has a sell rating (39/100 AI Score), but Reddit is talking about it incessantly and feels bullish about the stock. That signal combined with institutional bids to keep $INTC alive could outweigh its poor stock rating.
We’re always intrigued when we see stocks that AltIndex’s AI model rates as a buy (score of 60+) that are also getting a lot of traction on Reddit. The ones to note here are NVID, OKLO, GOOG, and IREN.
Brought to you by AltIndex.
📊 IPOs
PhonePe confidentially filed for an IPO that could raise up to 1.5 billion and value the Walmart-backed payments giant at 15 billion; stock reaction not yet available.
Fermi, co-founded by former Energy Secretary Rick Perry, targeted a 13.16 billion valuation in its IPO, seeking to raise 550 million to fund its nuclear, gas, and solar-powered data complex; the stock has not yet begun trading.
Medline weighed a 5 billion IPO filing as soon as October, potentially the biggest US listing this year for the Blackstone, Carlyle, and Hellman & Friedman-backed medical supplies maker; stock reaction not yet available.
🎙 What Do You Think?
Will you start day trading if the $25,000 rule is replaced?
🎤️ What you said last time
🎪 Crowdfunding Showcase
Bao’d Up, an innovative startup bringing Asian-fusion to the fast casual market, has hit its first funding goal. The CEO has global experience at Starbucks, Disney, Planet Fitness, and Alamo Drafthouse. Become an investor→
🧠 The Missing (Market) Links
South Park’s episode last night was about prediction markets, featuring Polymarket.
In South Korea, day trading is treated like an esports event with live betting. Check the wild footage.
Walmart’s going big on soccer. It’s teaming up with La Liga to become the first presenting partner of “El Clásico.” Goal: get Americans more into soccer.
The NFL Bears deal valued the team at a record $8.9 billion, topping the $8.6 billion 49ers stake sale from May.
New home sales spiked 20.5% in August to an 800,000 annualized pace, the highest since early 2022. Economists called it a fluke, warning the surge would likely reverse.
📜 Quote of the Day
“Investing isn’t about beating others at their game. It’s about controlling yourself at your own game.”
📢 We want to hear from you
We love hearing from you, and we deeply appreciate your feedback.
⭐️ What did you think of today's edition?
That’s all for today. Did we miss anything? Smash the reply button to let me know.
Cheers,
Brandon & Blake of Invested Inc
The information provided in Stocks & Income is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. Stocks & Income is not a registered investment advisor, broker-dealer, or licensed financial planner. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We may hold positions in or receive compensation from the companies or products mentioned. Disclosures will be made where applicable.
Stocks & Income, AltIndex, Finance Wrapped, The Chain, and Future Funders are all owned by Invested, Inc.